Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
| Status: | Completed |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/4/2013 |
| Start Date: | December 2011 |
| End Date: | September 2012 |
A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
The purpose of this study is to evaluate the effectiveness of 3 dose strengths of CT327
ointment (0.05%, 0.1% and 0.05% w/w) compared to a placebo, when applied twice daily for up
to 8 weeks, to the psoriatic plaques of patients with psoriasis vulgaris.
Inclusion Criteria:
- Male and female subjects aged at least 18 years.
- Stable psoriasis vulgaris
Exclusion Criteria:
- Subjects with guttate, erythrodermic, exfoliative or pustular psoriasis.
We found this trial at
8
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials